Ovid Therapeutics's EBIT per Share for the
three
months ended in Dec. 2023 was $-0.26.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.84.
During the past 3 years, the average EBIT per Share Growth Rate was 15.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Ovid Therapeutics's EBIT per Share or its related term are showing as below:
OVID'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -47.3 Med: 15.5 Max: 25.4
Current: 15.5
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Ovid Therapeutics was 25.40% per year. The lowest was -47.30% per year. And the median was 15.50% per year.
OVID's 3-Year EBIT Growth Rate is ranked better than 66.44% of 1305
companies
in the Biotechnology industry
Industry Median: 3.5
vs OVID: 15.50
The historical data trend for Ovid Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.84
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics (NAS:OVID) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Ovid Therapeutics EBIT per Share Related Terms
Thank you for viewing the detailed overview of Ovid Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Ovid Therapeutics (Ovid Therapeutics) Business Description
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OVID has been successfully added to your 